These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7249126)

  • 21. The economic burden of exposure to secondhand smoke for child and adult never smokers residing in U.S. public housing.
    Mason J; Wheeler W; Brown MJ
    Public Health Rep; 2015; 130(3):230-44. PubMed ID: 25931627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative pharmaco-economic analysis of docetaxel with cisplatin and cyclophosphamide with cisplatin in first-line chemotherapy of advanced ovarian cancer].
    Gorbunova VA; Khokhlova SV; Komarova BP; Orel NF; Besova NS
    Vopr Onkol; 2002; 48(6):695-9. PubMed ID: 12530266
    [No Abstract]   [Full Text] [Related]  

  • 23. Economic burden of road traffic injuries: a micro-costing approach.
    Riewpaiboon A; Piyauthakit P; Chaikledkaew U
    Southeast Asian J Trop Med Public Health; 2008 Nov; 39(6):1139-49. PubMed ID: 19062706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medicaid prepayment: concept and implementation.
    Hester J; Sussman E
    Milbank Mem Fund Q Health Soc; 1974; 52(4):415-44. PubMed ID: 4216862
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of co-payment for outpatient utilization among Medical Aid beneficiaries in Korea: A 5-year time series study.
    Yoo KB; Ahn HU; Park EC; Kim TH; Kim SJ; Kwon JA; Lee SG
    Health Policy; 2016 Aug; 120(8):960-6. PubMed ID: 27499450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
    Armstrong A; Otvos B; Singh S; Debernardo R
    Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis.
    Greving JP; Vernooij F; Heintz AP; van der Graaf Y; Buskens E
    Gynecol Oncol; 2009 Apr; 113(1):68-74. PubMed ID: 19176236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health care insurance premiums project.
    Mich Med; 1999 Feb; 98(2):19-21. PubMed ID: 10074773
    [No Abstract]   [Full Text] [Related]  

  • 29. Economic cost of cancer in the United States, 1980.
    Hodgson TA
    Prog Clin Biol Res; 1983; 132E():373-82. PubMed ID: 6647477
    [No Abstract]   [Full Text] [Related]  

  • 30. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
    Behbakht K; Cohn DE; Straughn JM
    Gynecol Oncol; 2018 Oct; 151(1):4-5. PubMed ID: 30068488
    [No Abstract]   [Full Text] [Related]  

  • 31. The cost of accidents and injuries at an institution for retarded adults.
    Pierce CH
    Ment Retard; 1977 Dec; 15(6):23-4. PubMed ID: 927152
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness of early-initiated treatment for advanced-stage epithelial ovarian cancer patients: a modeling study.
    Hoyer T; Bekkers R; Gooszen H; Massuger L; Rovers M; Grutters JP
    Int J Gynecol Cancer; 2014 Jan; 24(1):75-84. PubMed ID: 24362714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Centralisation of services for the management of ovarian cancer: arguments for.
    Olaitan A; McCormack M
    BJOG; 2007 Oct; 114(10):1188-90. PubMed ID: 17877670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomics of amifostine in ovarian cancer.
    Calhoun EA; Bennett CL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):102-7. PubMed ID: 10348268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Community health centers: an initiative of enduring utility.
    Freeman HE; Kiecolt KJ; Allen HM
    Milbank Mem Fund Q Health Soc; 1982; 60(2):245-67. PubMed ID: 6919771
    [No Abstract]   [Full Text] [Related]  

  • 36. Economic burden of metastatic bone disease in the U.S.
    Schulman KL; Kohles J
    Cancer; 2007 Jun; 109(11):2334-42. PubMed ID: 17450591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of cost-effectiveness studies in ovarian cancer.
    Sfakianos GP; Havrilesky LJ
    Cancer Control; 2011 Jan; 18(1):59-64. PubMed ID: 21273981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The costs of membership aging in a Blue Cross and Blue Shield plan.
    Jones SP
    Inquiry; 1985; 22(2):201-5. PubMed ID: 3159675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer care cost in Japan.
    Maeda N
    Prog Clin Biol Res; 1983; 132E():403-10. PubMed ID: 6647481
    [No Abstract]   [Full Text] [Related]  

  • 40. The excess medical cost and health problems of family members of persons diagnosed with alcohol or drug problems.
    Ray GT; Mertens JR; Weisner C
    Med Care; 2007 Feb; 45(2):116-22. PubMed ID: 17224773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.